Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL)

Historical Holders from Q2 2021 to Q3 2025

Symbol
LYEL on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
19.3M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
650K
Holdings value
$10.6M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
2
Number of buys
1
Number of sells
-4
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.003%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARCH Venture Fund IX, L.P. 13.1% $17.2M 36.6M Robert Nelsen 31 Dec 2024
Foresite Capital Fund IV, L.P. 9.2% +35.7% $12.8M $3.61M 27.2M +39.4% James B. Tananbaum 31 Mar 2025
BlackRock, Inc. 4.5% $6.23M 13.3M BlackRock, Inc. 31 Dec 2024
Explore Investments LLC/DE 5.4% $9.2M 1.04M Explore Investments LLC 25 Jul 2025

Institutional Holders of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 650K $10.6M -$15.7M $16.24 2
2025 Q2 2.44M $21.6M -$465M $8.84 6
2025 Q1 152M $81.8M +$816K $0.54 111
2024 Q4 150M $95.9M +$14.6M $0.64 101
2024 Q3 128M $177M -$7.29M $1.38 115
2024 Q2 133M $194M -$1.43M $1.45 114
2024 Q1 133M $297M +$3.77M $2.23 124
2023 Q4 131M $255M +$1.52M $1.94 116
2023 Q3 123M $180M +$238K $1.47 102
2023 Q2 122M $389M +$15.2M $3.18 98
2023 Q1 118M $278M +$605K $2.36 97
2022 Q4 117M $405M +$13.8M $3.47 94
2022 Q3 112M $824M +$50.7M $7.33 88
2022 Q2 106M $689M +$42.2M $6.52 72
2022 Q1 99.5M $503M +$55.4M $5.05 78
2021 Q4 85.5M $662M -$22.1M $7.74 76
2021 Q3 82.5M $1.22B +$39.8M $14.80 61
2021 Q2 79.7M $1.29B +$1.29B $16.24 52